...yes novel biotechs are not valued so much on what even potential sales they will have, but the perceived importance and value a said drug or procedure or device will have; its why there are so many Phase I and II biotechs that trade over $20 a share, yet they may never make a dime, as their drugs may never pass Phase II, let alone Phase III one day.
And with breast cancer, a great idea and device tied into the new Internet of Things, with the sponsoring so closely with giant bellweather Cisco, puts the value to me very much higher then here.
Any post i see of this value at a buyout, or this pps value based on future sales....are kinda ridiculous. No one is factoring the 7,000 pound gorilla breast cancer, and what a product like this could do for women...women around the world without access to mamograms, and just plain old privacy and convenience for women who dont want to get a mamogram.....how people miss this and talk about the pps with this or that is say lol .018 cents a share is uterrly ridiculous to me. The perceived value of the iTbra, to me, is exponentially higher.
Market Data 
Markets 
AI
